The DOI matches its Crossref record; 157 of the 162 references it cites were found in a registry or an index.
RAS Proteins and Their Regulators in Human Disease
Open accessAbstract
RAS proteins are binary switches, cycling between ON and OFF states during signal transduction. These switches are normally tightly controlled, but in RAS-related diseases, such as cancer, RASopathies, and many psychiatric disorders, mutations in the RAS genes or their regulators render RAS proteins persistently active. The structural basis of the switch and many of the pathways that RAS controls are well known, but the precise mechanisms by which RAS proteins function are less clear. All RAS biology occurs in membranes: a precise understanding of RAS' interaction with membranes is essential to understand RAS action and to intervene in RAS-driven diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, farnesylation at the position 185 cysteine residue results in KRAS anchoring at the plasma membrane, initiating the activation of KRAS and its downstream signaling42.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Post-translational modification of KRAS plays an important role in KRAS–MAPK pathway activation.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“KRAS is one of the most frequently mutated oncogenes in cancer, yet efforts to directly target KRAS have been mostly unsuccessful because initial analyses of KRAS proteins indicated that they lack a clear pocket to which small molecules can bind with high affinity [1, 2].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Although KRAS mutations are often collectively classified as a single oncogenic entity, distinct KRAS alleles exhibit substantial biochemical and functional heterogeneity [1,4,12].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [4]
In the citing paper
“Mutational activation of KRAS promotes the initiation and progression of cancers, especially in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific activating missense mutations.”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“However, it is frequently mutated in only a handful of cancers, with the highest frequencies in colorectal adenocarcinoma (COAD), lung adenocarcinoma (LUAD), multiple myeloma (MM), and pancreatic adenocarcinoma (PAAD).”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“KRAS is one of the most commonly mutated genes in cancer1,2”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“When mutated at one of its four hotspot codons—12, 13, 61, or 146—activated KRAS protein hyperactivates many downstream effector pathways, such as the MAPK and PI3K-AKT signaling pathways1”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“As protein tyrosine phosphorylation plays an essential role in multiple intracellular processes, SHP2 is involved in the regulation of multiple signaling pathways, including those involved in cancer cells, such as RAS-MAPK, PI3K-AKT and JAK-STAT pathways.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [261]
In the citing paper
“RAS acts as a molecular switch, transmitting signals of cell growth and differentiation by binding to GTP or GDP and switching between active and inactive states.261”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [261]
In the citing paper
“abnormalities in components of the RAS pathway, including activating RAS mutations, are common across a diverse range of malignancies”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“The RAS family GTPases, KRAS, NRAS and HRAS, cycle between GTP-loaded ‘on’ and GDP-loaded ‘off’ states4,6, involving the action of RAS-guanine nucleotide exchange factors (RAS-GEFs) and RAS-GTPase-activating proteins (RAS-GAPs), respectively.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“Almost all cancer-associated RAS mutations (~95%) affect codon 12, 13 or 61, and lead to a markedly increased basal RAS-GTP:RAS-GDP ratio and constitutive activation of RAS effectors4,6.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“When mutated, oncogenic RAS remains preferentially in the active GTP-bound state, whereas GTP hydrolysis by its GTPase function and enzymes such as GTPase-activating proteins, is compromised1,2.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [1]
In the citing paper
“KRAS in particular, is among the most frequently mutated oncogenes in cancer and is commonly associated with therapeutic resistance and poor prognosis1,5,6.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [1]
In the citing paper
“These mutations dramatically shift the equilibrium of Ras protein to exist mostly in the GTP-bound state and effectively uncouple Ras proteins from upstream receptor inputs and drive constitutive signaling to downstream Ras effector pathways (13).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [13]
In the citing paper
“On the one hand, the affinity of KRAS and GTP is at the pM level, while the concentration of GTP in cells is up to 0.5 μM.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [18]
In the citing paper
“It is difficult to achieve effective competition like protein kinase inhibitors [18, 19].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [18]
In the citing paper
“Oncogenic KRAS can activate various downstream effector pathways, and the best characterized are phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinases (MAPK) (23–25).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [24]
In the citing paper
“we recognize that these elements have a substantial influence on KRAS dynamics [53,54] and signaling [55].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,775
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Regulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211
Self-citationDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Milburn, M. V., Tong, L., deVos, A. M., Brünger, A. T., Yamaizumi, Z., Nishimura, S., & Kim, S. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,062
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
Flagged first, then by citations
5 of the 162 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 1,005
Nanodiscs: A Controlled Bilayer Surface for the Study of Membrane Proteins
McLean, M. A., Gregory, M. C., & Sligar, S. G. (2018) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-070816-033620 · Cited by 78
Lee, K., Fang, Z., Enomoto, M., Gasmi-Seabrook, G. M. C., Zheng, L., Koide, S., Ikura, M., & Marshall, C. B. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202001758 · Cited by 78
The duality of human oncoproteins: drivers of cancer and congenital disorders
Castel, P., Rauen, K. A., & McCormick, F. P. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0256-z · Cited by 80
Self-citationRas and Rap Signal Bidirectional Synaptic Plasticity via Distinct Subcellular Microdomains
Zhang, L., Zhang, P., Wang, G., Zhang, H., Zhang, Y., Yu, Y., Zhang, M., Xiao, J., Crespo, P., Hell, J. W., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.03.049 · Cited by 76
Zhang, J., & Feng, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854674 · Cited by 79
Exploring Nanocarriers as Treatment Modalities for Skin Cancer
Adnan, M., Akhter, M. H., Afzal, O., Altamimi, A. S. A., Ahmad, I. S., Alossaimi, M. A., Jaremko, M., Emwas, A.-H. M., Haider, T., & Haider, M. F. (2023) · Molecules · doi:10.3390/molecules28155905 · Cited by 78
Structures of N-terminally processed KRAS provide insight into the role of N-acetylation
Dharmaiah, S., Tran, T. H., Messing, S. A. J., Agamasu, C., Gillette, W., Yan, W., Waybright, T. J., Alexander, P., Esposito, D., Nissley, D. V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46846-w · Cited by 77
Self-citationTargeting Krasg12c‐mutant cancer with a mutation‐specific inhibitor
Christensen, J. G., Olson, P., Briere, T., Wiel, C., & Bergö, M. O. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13057 · Cited by 77
Chour, A., Denis, J., Mascaux, C., Zysman, M., Bigay-Game, L., Swalduz, A., Gounant, V., Cortot, A. B., Darrason, M., Fallet, V., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.013 · Cited by 78
SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype
Motta, M., Fasano, G., Gredy, S., Brinkmann, J., Bonnard, A. A., Şimşek‐Kiper, P. Ö., Güleç, E. Y., Essaddam, L., Ütine, G. E., Prandi, I. G., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.09.007 · Cited by 76
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 84
Melanogenesis and the Targeted Therapy of Melanoma
Li, C., Kuai, L., Cui, R., & Miao, X. (2022) · Biomolecules · doi:10.3390/biom12121874 · Cited by 83
Tkacik, E., Li, K., Pino, G. L. G., Ha, B. H., Viñals, J., Park, E., Beyett, T. S., & Eck, M. J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104634 · Cited by 72
The Function of RAS Mutation in Cancer and Advances in its Drug Research
Chen, S., Li, F., Xu, D., Hou, K., Fang, W., & Li, Y. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190506122228 · Cited by 75
A Structure is Worth a Thousand Words: New Insights for RAS and RAF Regulation
Simanshu, D. K., & Morrison, D. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1494 · Cited by 70
Self-citationYang, J.-M., Bhattacharya, S., West‐Foyle, H., Hung, C., Wu, T. ‐., Iglesias, P. A., & Huang, C. (2018) · Nature Communications · doi:10.1038/s41467-018-07150-9 · Cited by 70
Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome–Associated Cardiomyopathy
Hanses, U., Kleinsorge, M., Roos, L., Yigit, G., Li, Y., Barbarics, B., El‐Battrawy, I., Lan, H., Tiburcy, M., Hindmarsh, R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044794 · Cited by 74
Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts
Dunnett-Kane, V., Burkitt-Wright, E., Blackhall, F. H., Malliri, A., Evans, D. G., & Lindsay, C. R. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.291 · Cited by 66
Discovery of KRAS(G12D) selective degrader ASP3082
Yoshinari, T., Nagashima, T., Ishioka, H., Inamura, K., Nishizono, Y., Tasaki, M., Iguchi, K., Suzuki, A., Sato, C., Nakayama, A., et al. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01662-4 · Cited by 78
The Role of the Microbiome in the Etiopathogenesis of Colon Cancer
Tekle, G. E., Andreeva, N., & Garrett, W. S. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-025619 · Cited by 78
Li, Z., Prakash, P., & Buck, M. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00593 · Cited by 71
Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line
Pudewell, S., Wittich, C., Jasemi, N. S. K., Bazgir, F., & Ahmadian, M. R. (2021) · Communications Biology · doi:10.1038/s42003-021-02149-3 · Cited by 75
A structural model of a Ras–Raf signalosome
Mysore, V. P., Zhou, Z.-W., Ambrogio, C., Li, L., Kapp, J. N., Lu, C., Wang, Q., Tucker, M. R., Okoro, J. J., Nagy‐Davidescu, G., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00667-6 · Cited by 69
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Oya, Y., Imaizumi, K., & Mitsudomi, T. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107886 · Cited by 73
NF-κB, Mesenchymal Differentiation and Glioblastoma
Yamini, B. (2018) · Cells · doi:10.3390/cells7090125 · Cited by 71
Coupled membrane lipid miscibility and phosphotyrosine-driven protein condensation phase transitions
Chung, J. K., Huang, W. Y. C., Carbone, C. B., Nocka, L. M., Parikh, A. N., Vale, R. D., & Groves, J. T. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.09.017 · Cited by 69
Palmitoylation as a Key Regulator of Ras Localization and Function
Busquets-Hernández, C., & Triola, G. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.659861 · Cited by 74
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
Wang, C., Zhang, Y., Wang, J., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113906 · Cited by 73
Computer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 72
Recent advances in the role of sphingosine 1‐phosphate in cancer
Pyne, N. J., & Pyne, S. (2020) · FEBS Letters · doi:10.1002/1873-3468.13933 · Cited by 69
Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations
Choi, J., Goulding, S. P., Conn, B. P., McGann, C. D., Dietze, J. L., Kohler, J., Lenkala, D., Boudot, A. J., Rothenberg, D., Turcott, P. J., et al. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100084 · Cited by 70
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 69
Riedl, J. M., Fece de la Cruz, F., Lin, J. J., Parseghian, C., Kim, J. E., Matsubara, H., Barnes, H., Caughey, B., Norden, B. L., Morales-Giron, A. A., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.01.020 · Cited by 68
Guan, H., Toraldo, G., Cerda, S. R., Godley, F. A., Rao, S. R., McAneny, D. B., Doherty, G. M., Braverman, L. E., & Lee, S. L. (2020) · Thyroid · doi:10.1089/thy.2019.0116 · Cited by 68
Yan, W., Markegard, E., Dharmaiah, S., Urisman, A., Drew, M. R., Esposito, D., Scheffzek, K., Nissley, D. V., McCormick, F. P., & Simanshu, D. K. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107909 · Cited by 68
Self-citationSantarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3438 · Cited by 67
Priemer, D. S., Vortmeyer, A. O., Zhang, S., Chang, H. Y., Curless, K. L., & Liang Cheng, C. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.04.004 · Cited by 70
Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage
Ternet, C., & Kiel, C. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00712-3 · Cited by 73
Signaling from RAS to RAF: The Molecules and Their Mechanisms
Jeon, H., Tkacik, E., & Eck, M. J. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052521-040754 · Cited by 64
Alawieh, D., Cysique-Foinlan, L., Willekens, C., & Renneville, A. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01054-2 · Cited by 70
Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer
Cheng, J., Li, Y., Wang, X., Dong, G., & Sheng, C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00929 · Cited by 69
Exploiting cancer’s drinking problem: regulation and therapeutic potential of macropinocytosis
Puccini, J., Badgley, M. A., & Bar‐Sagi, D. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.09.004 · Cited by 67
Wang, Y., Ji, D., Lei, C., Chen, Y., Qiu, Y., Li, X., Li, M., Ni, D., Pu, J., Zhang, J., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.044 · Cited by 64
Role of c-Src in Carcinogenesis and Drug Resistance
Raji, L. M., Tetteh, A., & Amin, A. R. M. R. (2023) · Cancers · doi:10.3390/cancers16010032 · Cited by 67
Progress in targeting RAS with small molecule drugs
McCormick, F. P. (2019) · Biochemical Journal · doi:10.1042/bcj20170441 · Cited by 64
Self-citationMonobodies as enabling tools for structural and mechanistic biology
Hantschel, O. D., Biancalana, M., & Koide, S. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.01.015 · Cited by 63
Berlak, M., Tucker, E. R., Dorel, M., Winkler, A., McGearey, A., Rodríguez-Fos, E., Costa, B. M. D., Barker, K. T., Fyle, E., Calton, E. A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01583-z · Cited by 65
The era of high-quality chemical probes
Licciardello, M. P., & Workman, P. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00291d · Cited by 61
An explainable AI-driven biomarker discovery framework for Non-Small Cell Lung Cancer classification
Dwivedi, K., Rajpal, A., Rajpal, S., Agarwal, M., Kumar, V., & Kumar, N., V (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106544 · Cited by 70
Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer
Vlahopoulos, S., Adamaki, M., Khoury, N., Zoumpourlis, V. C., & Boldogh, I. R. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.004 · Cited by 68
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
Linking Metabolic Reprogramming, Plasticity and Tumor Progression
Shuvalov, O., Daks, A., Fedorova, O., Petukhov, A., & Barlev, N. (2021) · Cancers · doi:10.3390/cancers13040762 · Cited by 63
Chen, L., Zhang, W., Chen, D., Yang, Q., Sun, S., Dai, Z., Li, Z., Liang, X., Chen, C., Jiao, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01367-x · Cited by 62
Cregg, J., Pota, K., Tomlinson, A. C. A., Yano, J. K., Marquez, A., Liu, Y., Schulze, C. J., Seamon, K. J., Holderfield, M. T., Wei, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02313 · Cited by 69
Tripathi, K., & Garg, M. (2018) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0441-3 · Cited by 62
Brubaker, D. K., Paulo, J. A., Sheth, S., Poulin, E. J., Popow, O., Joughin, B. A., Strasser, S. D., Starchenko, A., Gygi, S. P., Lauffenburger, D. A., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.07.006 · Cited by 57
“The failure to inhibit K-RAS has motivated the search for alternative therapeutic strategies targeting its downstream signaling effectors (Simanshu et al., 2017; Velho and Haigis, 2011).”
BackgroundTargeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Désage, A.-L., Léonce, C., Swalduz, A., & Ortiz‐Cuaran, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.796832 · Cited by 65
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105579 · Cited by 62
Thatikonda, V., Lyu, H., Jurado, S., Kostyrko, K., Bristow, C. A., Albrecht, C., Alpar, D., Arnhof, H., Bergner, O., Bosch, K., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00800-6 · Cited by 76
Frequent KRAS mutations in oncocytic papillary renal neoplasm with inverted nuclei
Tong, K., Zhu, W. P., Fu, H., Cao, F., Wang, S., Zhou, W., Liu, C., Chen, D., Fan, S., & Hu, Z. (2020) · Histopathology · doi:10.1111/his.14084 · Cited by 60
Huang, Y., Zhen, Y., Chen, Y., Sui, S., & Zhang, L. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115842 · Cited by 59
Targeting ferroptosis in gastric cancer: Strategies and opportunities
Le, J., Pan, G., Zhang, C., Chen, Y., Tiwari, A. K., & Qin, J. (2023) · Immunological Reviews · doi:10.1111/imr.13280 · Cited by 63
Optogenetic regulation of endogenous proteins
Redchuk, T. A., Karasev, M. M., Verkhusha, P. V., Donnelly, S. K., Hülsemann, M., Virtanen, J., Moore, H. M., Vartiainen, M. K., Hodgson, L., & Verkhusha, V. V. (2020) · Nature Communications · doi:10.1038/s41467-020-14460-4 · Cited by 59
SPRED proteins and their roles in signal transduction, development, and malignancyPreprint
Lorenzo, C., & McCormick, F. P. (2020) · Genes & Development · doi:10.1101/gad.341222.120 · Cited by 59
Self-citationThe Ins and Outs of RAS Effector Complexes
Kiel, C., Matallanas, D., & Kölch, W. (2021) · Biomolecules · doi:10.3390/biom11020236 · Cited by 59
Han, H., Lim, J. W., & Kim, H. (2019) · Nutrients · doi:10.3390/nu11092113 · Cited by 58
Cancer vaccines: Targeting KRAS-driven cancers
Zhang, Y., Ma, J., Zhang, H.-X., Jiang, Y., & Luo, W. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1733420 · Cited by 58
Wiesweg, M., Kasper, S., Worm, K., Herold, T., Reis, H., Sara, L., Metzenmacher, M., Abendroth, A., Darwiche, K., Aigner, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0634-0 · Cited by 55
PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy
Li, Y., Zhang, T., Liu, Q., & He, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00808 · Cited by 59
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58
KRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 70
Lee, Y., Phelps, C. E., Huang, T., Mostofian, B., Wu, L., Zhang, Y., Tao, K. X., Chang, Y. H., Stork, P. A., Gray, J. W., et al. (2019) · eLife · doi:10.7554/elife.46393 · Cited by 56
Targeting the α4–α5 dimerization interface of K-RAS inhibits tumor formation in vivo
Khan, I., Spencer-Smith, R., & O’Bryan, J. P. (2019) · Oncogene · doi:10.1038/s41388-018-0636-y · Cited by 54
Potential Effects of Coronaviruses on the Liver: An Update
Wang, X., Lei, J., Li, Z., & Yan, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.651658 · Cited by 56
Targeting the undruggable oncogenic KRAS: the dawn of hope
Asimgil, H., Ertetik, U., Çevik, N. C., Ekizce, M., Doğruöz, A., Gökalp, M., Sever, E. A., Istvánffy, R., Friess, H., Ceyhan, G. O., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153688 · Cited by 57
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 62
A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors
Weller, C. E., Burnett, G. L., Jiang, L., Chakraborty, S., Zhang, D., Vita, N. A., Dilly, J., Kim, E., Maldonato, B. J., Seamon, K. J., et al. (2025) · Science · doi:10.1126/science.ads0239 · Cited by 64
A massively parallel infrastructure for adaptive multiscale simulations
Natale, F. D., Bhatia, H., Carpenter, T. S., Neale, C., Kokkila-Schumacher, S. I. L., Oppelstrup, T., Stanton, L. G., Zhang, X., Sundram, S., Scogland, T., et al. (2019) · International Conference for High Performance Computing, Networking, Storage and Analysis (SC) · doi:10.1145/3295500.3356197 · Cited by 61
Self-citationStructure of the SHOC2–MRAS–PP1C complex provides insights into RAF activation and Noonan syndrome
Bonsor, D. A., Alexander, P., Snead, K., Hartig, N., Drew, M. R., Messing, S. A. J., Finci, L. I., Nissley, D. V., McCormick, F. P., Esposito, D., et al. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00841-4 · Cited by 54
Self-citationERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Timofeev, O. N., Giron, P., Lawo, S., Pichler, M., & Noeparast, A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00554-5 · Cited by 63
The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling
Cui, Y., Groth, S., Troutman, S. A., Carlstedt, A., Sperka, T., Riecken, L. B., Kissil, J. L., Jin, H., & Morrison, H. (2019) · Oncogene · doi:10.1038/s41388-019-0883-6 · Cited by 53
Burns, T. F., Borghaei, H., Ramalingam, S. S., Mok, T. S. K., & Peters, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00744 · Cited by 58
Pituitary stalk interruption syndrome is characterized by genetic heterogeneity
Brauner, R., Bignon‐Topalovic, J., Bashamboo, A., & McElreavey, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242358 · Cited by 54
Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
Ottaiano, A., Normanno, N., Facchini, S., Cassata, A., Nappi, A. G., Romano, C., Silvestro, L., Stefano, A. D., Rachiglio, A. M., Roma, C., et al. (2020) · Cancers · doi:10.3390/cancers12071919 · Cited by 53
Post-translational modification of KRAS: potential targets for cancer therapy
Wang, W., Yuan, T., Qian, M., Yan, F., Yang, L., He, Q., Yang, B., Lu, J., & Zhu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00542-y · Cited by 54
Fu, L., Chen, S., He, G., Chen, Y., & Liu, B. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01244 · Cited by 53
Somekh, I., Marquardt, B., Liu, Y., Rohlfs, M., Hollizeck, S., Karakükçü, M., Ünal, E., Yilmaz, E. A., Patıroğlu, T., Cansever, M., et al. (2018) · Journal of Clinical Immunology · doi:10.1007/s10875-018-0533-8 · Cited by 53
Chida, K., Kotani, D., Masuishi, T., Kawakami, T., Kawamoto, Y., Kato, K., Fushiki, K., Sawada, K., Kumanishi, R., Shirasu, H., et al. (2021) · The Oncologist · doi:10.1002/onco.13870 · Cited by 50
Najafiyan, B., Hosseini, Z. B., Esmaelian, S., Firuzpour, F., Anaraki, S. R., Kalantari, L., Hheidari, A., Mesgari, H., & Nabi‐Afjadi, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116207 · Cited by 54
Molecular characterization and pathogenesis of gastrointestinal stromal tumor
Niinuma, T., Suzuki, H., & Sugai, T. (2018) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2018.01.02 · Cited by 55
RAS signalling in energy metabolism and rare human diseases
Dard, L., Bellancé, N., Lacombe, D., & Rossignol, R. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.05.003 · Cited by 56
Human endogenous retroviruses in cancer: Expression, regulation and function (Review)
Gao, Y., Yu, X., & Chen, T. (2020) · Oncology Letters · doi:10.3892/ol.2020.12382 · Cited by 56
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Sattler, M., Mohanty, A., Kulkarni, P., & Salgia, R. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.10.001 · Cited by 54
Allosteric Switching of Calmodulin in a Mycobacterium smegmatis porin A (MspA) Nanopore‐Trap
Liu, Y., Pan, T., Wang, K., Wang, Y., Yan, S., Wang, L., Zhang, S., Du, X., Jia, W., Zhang, P., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202110545 · Cited by 51
Issahaku, A. R., Salifu, E. Y., Agoni, C., Alahmdi, M. I., Abo-Dya, N. E., Soliman, M. E. S., Rudrapal, M., & Naresh, P. (2023) · ChemistrySelect · doi:10.1002/slct.202300277 · Cited by 53
Longo, J. F., Weber, S. M., Turner-Ivey, B., & Carroll, S. L. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000197 · Cited by 52
Cryo-EM structure of a RAS/RAF recruitment complex
Park, E., Rawson, S., Schmoker, A., Kim, B.-W., Oh, S., Song, K., Jeon, H., & Eck, M. J. (2023) · Nature Communications · doi:10.1038/s41467-023-40299-6 · Cited by 51
Bildik, G., Liang, X., Sutton, M. N., Bast, R. C., & Lü, Z. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0331 · Cited by 55
Metadata
- Authors
- Simanshu, D. K., Nissley, D. V., & McCormick, F.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- University of California, San Francisco (US)
- Corresponding author
- McCormick, Frank
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 170
- Issue
- 1
- Pages
- 17-33
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5555610
- OpenAlex
- W2732767128
- Cited by
- 1,943
- References
- 162
- Citations by year
- 2026: 210 · 2025: 263 · 2024: 276 · 2023: 247 · 2022: 267 · 2021: 247 · 2020: 194 · 2019: 143 · 2018: 82 · 2017: 12
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute
- NIH (HHSN261200800001E)
- Outstanding Investigator Award (5R35CA197709)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras proteins, Ras signaling, RASopathies, cancer, mental illness, RAS mutations, signal transduction, membrane binding, Ras activation
- MeSH terms
- Congenital Abnormalities, Animals, Mental Disorders, Cell Membrane, Humans, Mutation, Neoplasms, Phylogeny, Yeasts, Signal Transduction, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
